DNA repair defects in cancer and therapeutic opportunities

Signatures of TOP1 transcription-associated mutagenesis in cancer and germline

(2022) Martin A. M. Reijns et al.   NATURE

CARM1 regulates replication fork speed and stress response by stimulating PARP1

(2021) Marie-Michelle Genois et al.   MOLECULAR CELL

ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells

(2021) Priyanka Verma et al.   NATURE CELL BIOLOGY

Structure of the FA core ubiquitin ligase closing the ID clamp on DNA

(2021) Shengliu Wang et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Interfaces between cellular responses to DNA damage and cancer immunotherapy

(2021) Domenic Pilger et al.   GENES & DEVELOPMENT

Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors

(2021) Kasper Fugger et al.   SCIENCE

Loss of the abasic site sensor HMCES is synthetic lethal with the activity of the APOBEC3A cytosine deaminase in cancer cells

(2021) Josep Biayna et al.   PLOS BIOLOGY

Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells

(2021) Qianye Yang et al.   Frontiers in Pharmacology

Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors

(2021) Zhijun Zhou et al.   JAMA Network Open

Spatially organized multicellular immune hubs in human colorectal cancer

(2021) Karin Pelka et al.   CELL

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

(2021) Timothy A. Yap et al.   CLINICAL CANCER RESEARCH

The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells

(2021) Antoine Simoneau et al.   GENES & DEVELOPMENT

Implications of inhibition of Rev1 interaction with Y family DNA polymerases for cisplatin chemotherapy

(2021) Jung-Hoon Yoon et al.   GENES & DEVELOPMENT

BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies

(2021) Markus Berger et al.   JOURNAL OF MEDICINAL CHEMISTRY

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency

(2021) Ke Cong et al.   MOLECULAR CELL

REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps

(2021) Angelo Taglialatela et al.   MOLECULAR CELL

Mechanisms of BRCA1–BARD1 nucleosome recognition and ubiquitylation

(2021) Qi Hu et al.   NATURE

BARD1 reads H2A lysine 15 ubiquitination to direct homologous recombination

(2021) Jordan R. Becker et al.   NATURE

Cellular functions of the protein kinase ATM and their relevance to human disease

(2021) Ji-Hoon Lee et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress

(2021) Rebecca L Lloyd et al.   NUCLEIC ACIDS RESEARCH

Genetic vulnerabilities upon inhibition of DNA damage response

(2021) Chao Wang et al.   NUCLEIC ACIDS RESEARCH

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

(2021) Diana Zatreanu et al.   Nature Communications

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

(2021) Payal D. Shah et al.   GYNECOLOGIC ONCOLOGY

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

(2021) Jeffrey W. Johannes et al.   JOURNAL OF MEDICINAL CHEMISTRY

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

(2021) Anne Roulston et al.   MOLECULAR CANCER THERAPEUTICS

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

(2021) Dirk Brehmer et al.   MOLECULAR CANCER THERAPEUTICS

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps

(2021) Mariana Paes Dias et al.   MOLECULAR CELL

Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells

(2021) Stephanie Tirman et al.   MOLECULAR CELL

ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer

(2020) Shahrzad Rafiei et al.   CANCER RESEARCH

SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications

(2020) Shalini Singh et al.   LEUKEMIA

CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells

(2020) Rebecca F. Rogers et al.   CANCER RESEARCH

BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases

(2020) Malwina Suszynska et al.   Journal of Ovarian Research

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma

(2020) Hailong Sheng et al.   Journal for ImmunoTherapy of Cancer

ATM-Deficient Cancers Provide New Opportunities for Precision Oncology

(2020) Nicholas R. Jette et al.   Cancers

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors

(2020) Praveen Vikas et al.   Frontiers in Oncology

BRG1 loss predisposes lung cancers to replicative stress and ATR dependency

(2020) Manav Gupta et al.   CANCER RESEARCH

Role of POLE and POLD1 in familial cancer

(2020) Pilar Mur et al.   GENETICS IN MEDICINE

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

(2020) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer

(2020) Joshua M. Abbott et al.   MOLECULAR CANCER THERAPEUTICS

Endogenous DNA 3′ Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease

(2020) Alejandro Álvarez-Quilón et al.   MOLECULAR CELL

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

(2020) Hyoung Kim et al.   Nature Communications

HMCES Maintains Replication Fork Progression and Prevents Double-Strand Breaks in Response to APOBEC Deamination and Abasic Site Formation

(2020) Kavi P.M. Mehta et al.   Cell Reports

A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response

(2020) Hao-Dong Li et al.   JCI Insight

Repeat expansions confer WRN dependence in microsatellite-unstable cancers

(2020) Niek van Wietmarschen et al.   NATURE

The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution

(2020) Alexej Ballhausen et al.   Nature Communications

First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

(2020) Timothy A. Yap et al.   Cancer Discovery

Cell Cycle Checkpoints Cooperate to Suppress DNA- and RNA-Associated Molecular Pattern Recognition and Anti-Tumor Immune Responses

(2020) Jie Chen et al.   Cell Reports

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

(2020) Mark T. J. van Bussel et al.   BRITISH JOURNAL OF CANCER

DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity

(2020) Changzheng Lu et al.   CANCER CELL

MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway

(2020) Junhong Guan et al.   CANCER CELL

The Oncogenic Helicase ALC1 Regulates PARP Inhibitor Potency by Trapping PARP2 at DNA Breaks

(2020) Charlotte Blessing et al.   MOLECULAR CELL

Two Aldehyde Clearance Systems Are Essential to Prevent Lethal Formaldehyde Accumulation in Mice and Humans

(2020) Felix A. Dingler et al.   MOLECULAR CELL

Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD

(2020) Graeme Hewitt et al.   MOLECULAR CELL

The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment

(2020) Szilvia Juhász et al.   Science Advances

Mutation Spectra of the MRN (MRE11, RAD50, NBS1/NBN) Break Sensor in Cancer Cells

(2020) Matthew T. McPherson et al.   Cancers

A high-throughput screen to identify novel small molecule inhibitors of the Werner Syndrome Helicase-Nuclease (WRN)

(2019) Joshua A. Sommers et al.   PLoS One

A recurrent cancer-associated substitution in DNA polymerase ε produces a hyperactive enzyme

(2019) Xuanxuan Xing et al.   Nature Communications

Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets

(2019) Kristen E. Mengwasser et al.   MOLECULAR CELL

R-Loops as Cellular Regulators and Genomic Threats

(2019) Madzia P. Crossley et al.   MOLECULAR CELL

ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment

(2019) Magnus T. Dillon et al.   CLINICAL CANCER RESEARCH

WRN helicase is a synthetic lethal target in microsatellite unstable cancers

(2019) Edmond M. Chan et al.   NATURE

BRCA1-associated R-loop affects transcription and differentiation in breast luminal epithelial cells

(2019) Huai-Chin Chiang et al.   NUCLEIC ACIDS RESEARCH

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

(2019) Constantia Pantelidou et al.   Cancer Discovery

Inadequate DNA Damage Repair Promotes Mammary Transdifferentiation, Leading to BRCA1 Breast Cancer

(2019) Hua Wang et al.   CELL

ATM in DNA repair in cancer

(2019) Mei Hua Jin et al.   PHARMACOLOGY & THERAPEUTICS

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

(2019) Kalindi Parmar et al.   CLINICAL CANCER RESEARCH

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2019) Antonio González-Martín et al.   NEW ENGLAND JOURNAL OF MEDICINE

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

(2019) Robert L. Coleman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types

(2019) Feng Wang et al.   JAMA Oncology

Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer

(2019) Victor Quereda et al.   CANCER CELL

PRIMPOL-Mediated Adaptive Response Suppresses Replication Fork Reversal in BRCA-Deficient Cells

(2019) Annabel Quinet et al.   MOLECULAR CELL

Structure of the Fanconi anaemia monoubiquitin ligase complex

(2019) Shabih Shakeel et al.   NATURE

WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells

(2019) Tatiana N. Moiseeva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

(2019) Jacqueline H. L. Fok et al.   Nature Communications

FANCM suppresses DNA replication stress at ALT telomeres by disrupting TERRA R-loops

(2019) Xiaolei Pan et al.   Scientific Reports

First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy

(2019) Pamela Munster et al.   Cancer Management and Research

DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity

(2018) Rajat Gupta et al.   CELL

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

(2018) Jung-Min Lee et al.   LANCET ONCOLOGY

The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations

(2018) Liang Chen et al.   MOLECULAR CELL

DNA Replication Determines Timing of Mitosis by Restricting CDK1 and PLK1 Activation

(2018) Bennie Lemmens et al.   MOLECULAR CELL

The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication

(2018) Hana Hanzlikova et al.   MOLECULAR CELL

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells

(2018) Harveer Dev et al.   NATURE CELL BIOLOGY

Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing

(2018) Sarah V. Gerhart et al.   Scientific Reports

BRCA2 Regulates Transcription Elongation by RNA Polymerase II to Prevent R-Loop Accumulation

(2018) Mahmud K.K. Shivji et al.   Cell Reports

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells

(2018) Marco Barazas et al.   Cell Reports

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

(2018) Stephen T. Durant et al.   Science Advances

Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes

(2018) Hai Dang Nguyen et al.   CANCER RESEARCH

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation

(2018) Frank P. Vendetti et al.   JOURNAL OF CLINICAL INVESTIGATION

Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load

(2018) Hao-Dong Li et al.   JOURNAL OF CLINICAL INVESTIGATION

CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions

(2018) Michal Zimmermann et al.   NATURE

53BP1 cooperation with the REV7–shieldin complex underpins DNA structure-specific NHEJ

(2018) Hind Ghezraoui et al.   NATURE

The shieldin complex mediates 53BP1-dependent DNA repair

(2018) Sylvie M. Noordermeer et al.   NATURE

53BP1–RIF1–shieldin counteracts DSB resection through CST- and Polα-dependent fill-in

(2018) Zachary Mirman et al.   NATURE

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

An intrinsic S/G2 checkpoint enforced by ATR

(2018) Joshua C. Saldivar et al.   SCIENCE

PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes

(2018) Pierre-Jacques Hamard et al.   Cell Reports

Localized protein biotinylation at DNA damage sites identifies ZPET, a repressor of homologous recombination

(2018) David M. Moquin et al.   GENES & DEVELOPMENT

USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors

(2018) Kah Suan Lim et al.   MOLECULAR CELL

DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells

(2018) Yizhou Joseph He et al.   NATURE

Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition

(2018) Chao Wang et al.   ONCOGENE

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

(2018) Liya Ding et al.   Cell Reports

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells

(2017) Stephanie A. Yazinski et al.   GENES & DEVELOPMENT

Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Protects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes

(2017) Jeremy J. Ratiu et al.   JOURNAL OF IMMUNOLOGY

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Robert L Coleman et al.   LANCET

Coupling of Homologous Recombination and the Checkpoint by ATR

(2017) Rémi Buisson et al.   MOLECULAR CELL

Replication Fork Reversal: Players and Guardians

(2017) Annabel Quinet et al.   MOLECULAR CELL

Mechanism of tandem duplication formation in BRCA1-mutant cells

(2017) Nicholas A. Willis et al.   NATURE

The essential kinase ATR: ensuring faithful duplication of a challenging genome

(2017) Joshua C. Saldivar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A mitosis-specific and R loop–driven ATR pathway promotes faithful chromosome segregation

(2017) Lilian Kabeche et al.   SCIENCE

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells

(2017) Hiro Sato et al.   Nature Communications

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells

(2017) Pepijn M. Schoonen et al.   Nature Communications

Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis

(2017) Xiaowen Zhang et al.   Nature Communications

MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells

(2017) Delphine Lemaçon et al.   Nature Communications

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

(2016) Benjamin H. Lok et al.   CLINICAL CANCER RESEARCH

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models

(2016) Hyoung Kim et al.   CLINICAL CANCER RESEARCH

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

(2016) Suzanne Leijen et al.   JOURNAL OF CLINICAL ONCOLOGY

HELB Is a Feedback Inhibitor of DNA End Resection

(2016) Ján Tkáč et al.   MOLECULAR CELL

A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors

(2016) Sergio Ruiz et al.   MOLECULAR CELL

Replication fork stability confers chemoresistance in BRCA-deficient cells

(2016) Arnab Ray Chaudhuri et al.   NATURE

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

(2016) Chris T. Williamson et al.   Nature Communications

ATM protein is deficient in over 40% of lung adenocarcinomas

(2016) Liza C. Villaruz et al.   Oncotarget

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

(2016) Junko Murai et al.   Oncotarget

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

(2016) Shawn F. Johnson et al.   Cell Reports

Co-transcriptional R-loops are the main cause of estrogen-induced DNA damage

(2016) Caroline Townsend Stork et al.   eLife

The Fanconi Anemia Pathway Maintains Genome Stability by Coordinating Replication and Transcription

(2015) Rebekka A. Schwab et al.   MOLECULAR CELL

Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase

(2015) Rémi Buisson et al.   MOLECULAR CELL

Targeting the DNA Damage Response in Cancer

(2015) Mark J. O’Connor   MOLECULAR CELL

Promotion of BRCA2-Dependent Homologous Recombination by DSS1 via RPA Targeting and DNA Mimicry

(2015) Weixing Zhao et al.   MOLECULAR CELL

BRCA1 Recruitment to Transcriptional Pause Sites Is Required for R-Loop-Driven DNA Damage Repair

(2015) Elodie Hatchi et al.   MOLECULAR CELL

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair

(2015) Raphael Ceccaldi et al.   NATURE

Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination

(2015) Pedro A. Mateos-Gomez et al.   NATURE

REV7 counteracts DNA double-strand break resection and affects PARP inhibition

(2015) Guotai Xu et al.   NATURE

Replication fork reversal in eukaryotes: from dead end to dynamic response

(2015) Kai J. Neelsen et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

(2015) R. L. Flynn et al.   SCIENCE

The Fanconi Anemia Pathway Protects Genome Integrity from R-loops

(2015) María L. García-Rubio et al.   PLoS Genetics

Cancers associated withBRCA1andBRCA2mutations other than breast and ovarian

(2014) Jacqueline Mersch et al.   CANCER

ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency

(2014) K. N. Mohni et al.   CANCER RESEARCH

RPA Inhibition Increases Replication Stress and Suppresses Tumor Growth

(2014) J. G. Glanzer et al.   CANCER RESEARCH

BRCA1 controls homologous recombination at Tus/Ter-stalled mammalian replication forks

(2014) Nicholas A. Willis et al.   NATURE

BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2

(2014) Vaibhav Bhatia et al.   NATURE

Breast-Cancer Risk in Families with Mutations in PALB2

(2014) Antonis C. Antoniou et al.   NEW ENGLAND JOURNAL OF MEDICINE

ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA

(2013) Luis Ignacio Toledo et al.   CELL

Attenuating homologous recombination stimulates an AID-induced antileukemic effect

(2013) Kristin R. Lamont et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The ATM protein kinase: regulating the cellular response to genotoxic stress and more

(2013) Yosef Shiloh et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition

(2013) Matteo Berti et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity

(2013) Stephen J. Pettitt et al.   PLoS One

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

(2013) N. Johnson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Postreplicative Mismatch Repair

(2013) J. Jiricny   Cold Spring Harbor Perspectives in Biology

DNA Damage Sensing by the ATM and ATR Kinases

(2013) A. Marechal et al.   Cold Spring Harbor Perspectives in Biology

A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2

(2012) Katharina Schlacher et al.   CANCER CELL

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response

(2012) Britt Adamson et al.   NATURE CELL BIOLOGY

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

(2012) Janneke E. Jaspers et al.   Cancer Discovery

Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11

(2011) Katharina Schlacher et al.   CELL

Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice

(2011) Frédéric Langevin et al.   NATURE

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

(2011) Luis I Toledo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

(2010) Samuel F. Bunting et al.   CELL

The DNA Damage Response: Making It Safe to Play with Knives

(2010) Alberto Ciccia et al.   MOLECULAR CELL

Synthesis-dependent microhomology-mediated end joining accounts for multiple types of repair junctions

(2010) Amy Marie Yu et al.   NUCLEIC ACIDS RESEARCH

Rad52 inactivation is synthetically lethal with BRCA2 deficiency

(2010) Z. Feng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-Stranded DNA Orchestrates an ATM-to-ATR Switch at DNA Breaks

(2009) Bunsyo Shiotani et al.   MOLECULAR CELL

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA polymerase   and   proofreading suppress discrete mutator and cancer phenotypes in mice

(2009) T. M. Albertson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Remodeling of DNA replication structures by the branch point translocase FANCM

(2008) K. Gari et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA